CRISTAL DELIVERY BV

Their core work

Cristal Delivery is a Dutch nanomedicine SME developing polymeric nanoparticle drug-delivery systems, built around their proprietary CriPec platform technology. They engineer nanoparticles that can carry cancer drugs or imaging agents specifically to tumour tissue, improving precision and reducing side effects compared to conventional chemotherapy. Their work sits at the intersection of pharmaceutical chemistry, oncology, and medical imaging — turning lab-stage nanomedicine into clinically viable products. They operate as a spin-out-style commercial company, not a research institute, meaning their focus is getting these technologies to market.

What they specialise in

How they've shifted over time

Between 2017 and 2020, their anchor project INTACT pursued the full imaging + therapy package — combining nuclear medicine imaging with nanoparticle delivery as a precision oncology product candidate. By 2020-2021, the smaller ICARUS project shifted focus to a more fundamental question: how exactly their CriPec nanomedicines distribute within tumour tissue. The trajectory suggests they moved from ambitious commercial-scale development toward targeted scientific validation, likely to strengthen the evidence base behind the same platform.

They appear to be consolidating scientific evidence around their CriPec platform rather than expanding into new technology areas, which points to a company refining a specific product toward clinical or regulatory milestones.

How they like to work

Cristal Delivery operates as a sole coordinator in both recorded H2020 projects, with no consortium partners listed — a pattern typical of SME Instrument grants where the company drives its own R&D without a multi-partner consortium. This makes them a self-directed technology developer rather than a hub-style networker. Partnering with them likely means engaging directly with the company on their platform, not joining a wider coalition they have assembled.

No H2020 consortium partners are recorded, reflecting the single-beneficiary nature of their SME Instrument funding. Their geographic base is the Netherlands (Maastricht), with no cross-border partnerships visible in the data.

What sets them apart

Unlike the many university nanomedicine groups in Europe, Cristal Delivery is a commercial SME with a named proprietary platform (CriPec) and EU validation that it was deemed market-ready enough for an SME-2 grant of EUR 2.5M. They are the kind of partner a consortium brings in when it needs an actual product-oriented nanoparticle technology rather than another academic lab. Their Maastricht base also places them inside the Dutch life-sciences corridor.

Highlights from their portfolio

• INTACT
  Their flagship SME-2 project worth EUR 2.5M — a rare grant size signalling EU confidence that their cancer-targeting nanomedicine was close to market.
• ICARUS
  A focused follow-on study of how their CriPec nanomedicines actually distribute inside tumour tissue, showing they invest in validating the biology behind their own platform.